Circulating insulin-like growth factor II and colorectal adenomas.
AuthorsRenehan, Andrew G
Painter, John E
O'Halloran, Domhnall J
Atkin, Wendy S
Potten, Christopher S
O'Dwyer, Sarah T
Shalet, Stephen M
AffiliationDepartment of Surgery, Christie Hospital National Health Service Trust, Manchester, United Kingdom.
MetadataShow full item record
AbstractCirculating insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) may be risk factors for the development of colorectal cancer. On the other hand, IGF-II and IGFBP-2 are overexpressed in colorectal carcinomas. These contrasting backgrounds led us to investigate the relationship between serum IGF-I, IGF-II, IGFBP-2, and IGFBP-3 and the presence of colorectal adenomas, known precursors of colorectal carcinoma, in 345 volunteers attending a screening flexible sigmoidoscopy trial (entry criteria: healthy, aged 55-64 yr). The most striking finding was an elevated mean serum IGF-II in individuals with adenomas (n = 52) compared with controls (mean difference, 139 ng/mL; 95% confidence intervals, 82, 196; P < 0.0001). Logistic regression adjusting for confounding factors confirmed the significant association between IGF-II and adenoma occurrence (P < 0.0001) and revealed an additional positive association with serum IGFBP-2 (P < 0.0001). However, there was no association found between either serum IGF-I and/or IGFBP-3 and the presence of adenomas. Additionally, in 31 individuals with adenomas in whom levels were determined pre- and postpolypectomy, there was a significant fall in mean IGF-II (P < 0.001) and IGFBP-2 (P < 0.001) after adenoma removal, but no difference in IGF-II and IGFBP-2 concentrations between repeated samples in 20 individuals without adenomas. Immunohistochemical studies demonstrated IGF-II expression in 83% of all adenomas, which contrasted with absent expression in normal colonic expression and hyperplastic polyps. This study has shown for the first time that serum IGF-II may be a tumor marker in individuals with colorectal adenomas. Further studies are needed to validate these relationships in larger populations, including individuals undergoing colonoscopy.
CitationCirculating insulin-like growth factor II and colorectal adenomas. 2000, 85 (9):3402-8 J. Clin. Endocrinol. Metab.
JournalThe Journal of Clinical Endocrinology and Metabolism
- High-risk colorectal adenomas and serum insulin-like growth factors.
- Authors: Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O'Dwyer ST
- Issue date: 2001 Jan
- Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps.
- Authors: Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB, Rosen CJ
- Issue date: 2005 Aug
- Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer.
- Authors: Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST
- Issue date: 2000 Nov
- Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
- Authors: Nosho K, Yamamoto H, Taniguchi H, Adachi Y, Yoshida Y, Arimura Y, Endo T, Hinoda Y, Imai K
- Issue date: 2004 Dec 1
- No effect of red clover-derived isoflavone intervention on the insulin-like growth factor system in women at increased risk of colorectal cancer.
- Authors: Vrieling A, Rookus MA, Kampman E, Bonfrer JM, Bosma A, Cats A, van Doorn J, Korse CM, Witteman BJ, van Leeuwen FE, van't Veer LJ, Voskuil DW
- Issue date: 2008 Oct